 |
|
|
| |
Resistance Analysis of Genotype 1 or 3 HCV-Infected Patients
Treated With
Sofosbuvir/Velpatasvir + GS-9857 for 6 or 8 Weeks
|
| |
| |
Reported by Jules Levin
EASL 2016 april 14-17 Barcelona
Edward J. Gane,1 Evguenia S. Svarovskaia,2 Hadas Dvory-Sobol,2 Robert H. Hyland,2 Luisa M. Stamm,2 Diana M. Brainard,2 Michael D. Miller,2 Hongmei Mo,2 Christian Schwabe,1 Catherine A. Stedman3
1Auckland Clinical Studies Ltd, Auckland, New Zealand; 2Gilead Sciences, Inc., Foster City, California, USA; 3Christchurch Clinical Studies Trust, Christchurch, New Zealand
|
| |
|
|
|
|
|
